QiC Anticoagulation launches

NHS, industry and the charitable sector collaborate to spread best practice in the prevention and treatment of blood clots in the UK

The Quality in Care (QiC) partnership is proud to announce that its 2014 Anticoagulation Programme is now open for entry to teams and individuals working within the field of anticoagulation – a field of treatment involving the prevention and treatment of blood clots.

Launched today at the Clinical Pharmacy Congress 2014 in London, QiC Anticoagulation recognises, rewards and shares good practice in anticoagulation management, education and patient care.

The programme comprises both an awards event and subsequent dissemination opportunities, and has the support and active participation of key stakeholders, including Bayer and charity ACE (AntiCoagulation Europe).

Partnership working and collaboration are key to the QiC Programme and entries are invited from the NHS, industry, private sector and patient organisations to be reviewed by a panel of judges made up of nurses, commissioners, clinicians and patient representatives.

Eve Knight, co-founder and Chief Executive, AntiCoagulation Europe said: “ACE is proud to support the Quality in Care (QiC) Anticoagulation Programme because it shares our goals of recognising best practice and enabling patients to take a more active role in their own healthcare as well as improving their quality of life.”

Marion McPherson, General Medicine Business Unit Head, Bayer HealthCare commented: “Bayer is delighted to partner the Quality in Care 2014 Anticoagulation programme. Our products and services are designed to benefit people and improve their quality of life which is why we are proud to be associated with a programme that supports the implementation of innovation and good practice in the NHS, resulting in tangible benefits for patients.”

Winners of the 2014 awards will be announced at an event recognising good practice on Tuesday September 30, 2014, at BMA House, Tavistock Square, London.